He already presented Sunday 1pm for the Oral presentation, hence why they released the news to ASX.
Session details were in the previous ASX ann:
Session details:Oral Presentation Session:• First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation• Session S4: Clinical Trials in Movement Disorders, Sunday May 5, 1:00 pm US ET
• Presentation number 001Poster Presentation Sessions:• Abstract number 837; PBT434 Prevents α-Synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophyii•
Poster Session P5, Thursday May 9, 11:30am to 6:30pm US ET• Poster presentation number 8-006
ATH Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)